News & Resources

Latest News

This page is not intended for the general public. News releases issued by Kyowa Kirin are intended to inform media and investors of information related to the company's business in a fair manner. Though it may include information concerning pharmaceutical products (including products under development), it is not for the purpose of promoting, advertising or medical advice.

Kyowa Kirin announces positive interim real-world data for mogamulizumab (Poteligeo®) in cutaneous T-cell lymphoma at EORTC-CLTG 2024
Download
8 October 2024

Kyowa Kirin Presents Real-World Evidence Demonstrating Clinically Meaningful Impact of Burosumab Treatment in Adults with X-linked Hypophosphatemia
Download
1 October 2024

Kyowa Kirin to Present New Research Spotlighting Global Efforts to Advance Science and Patient Care in X-linked Hypophosphatemia at ASBMR Annual Meeting
Download
26 September 2024

New Analysis Demonstrates Impaired Work Productivity and Increased Unemployment Rates in Adults with X-linked Hypophosphataemia (XLH)
Download
10 September 2024

Kyowa Kirin International and NewBridge Pharmaceuticals enter into agreement to improve access to medicines for rare disease patients across Middle East and North Africa
Download
07 August 2024

Polish Ministry of Health approves reimbursement of POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome.
Download
31 July 2024

NICE enables access to first treatment that targets the underlying pathophysiology of rare disease X-linked hypophosphataemia (XLH) in adults.
Download
14 May 2024

CTCL Global Care Collaborative Pioneers Consensus for Improving Diagnosis and Care in Cutaneous T-Cell Lymphoma (CTCL).
Download
14 May 2024

First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of MF and SS.
Download
15 April 2024

Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases.
Download
24 January 2024

New Post Hoc Analysis from MAVORIC Trial Sheds Light on the Burden of Cutaneous T-Cell Lymphoma on Health-Related Quality of Life.
Download
11 December 2023

Kyowa Kirin Responds to NICE’s Publication of Appraisal Consultation Document for CRYSVITA® (Burosumab), for Treatment of Rare Disease X-Linked Hypophosphataemia (XLH) in Adults.
Download
29 November 2023

Kyowa Kirin demonstrates commitment to real-world evidence for POTELIGEO® (mogamulizumab) at EORTC 2023.
Download
21 September 2023

Grünenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration.
Download
2 August 2023

Scottish Medicines Consortium (SMC) Enables Access to First Treatment Tackling the Underlying Cause of X-Linked Hypophosphataemia (XLH) in Adults.
Download
13 February 2023

Grünenthal and Kyowa Kirin International announce Joint Venture Collaboration for established medicines portfolio.
24 November 2022
Download

Kyowa Kirin Appoints Abdul Mullick, President, Kyowa Kirin International, to New Global Role as Vice Chief International Business Officer; Jeremy Morgan appointed President, Kyowa Kirin International
08 November 2022
Download

Kyowa Kirin receives European Commission Approval for Use of CRYSVITA®▼(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO).
18 August 2022
Download

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA® ▼(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO).
28 June 2022
Download

New Real World Evidence Underlines Benefits of POTELIGEO®▼ (mogamulizumab) Treatment for Cutaneous T-cell Lymphoma (CTCL) Patients.
14 October 2021
Download

Long-term CRYSVITA® ▼ (burosumab) treatment reduces the burden of disease in adults with X-Linked Hypophosphataemia (XLH), a rare genetic metabolic bone disease.
24 September 2021
Download

Kyowa Kirin Announces EU Approval for the Self-administration of CRYSVITA® ▼ (burosumab) to Treat X-Linked Hypophosphataemia (XLH)
19 July 2021
Download

Kyowa Kirin welcomes the decision that the National Institute for Health and Care Excellence will revisit their appraisal of the innovative systemic treatment, POTELIGEO® (mogamulizumab), for adults living with two forms of ultra-rare non-Hodgkin lymphoma.
11 June 2021
Download

New Data Analysis Shows Link between Blood Involvement and Response to Treatment in Cutaneous T-cell Lymphoma (CTCL) Patients.
Download
11 June 2021

Kyowa Kirin Receives Positive CHMP Opinion for the Self-administration of CRYSVITA® ▼ (burosumab) to Treat X-Linked Hypophosphataemia (XLH), a Rare Metabolic Bone Disorder.
Download
07 May 2021

Kyowa Kirin responds to the National Institute for Health and Care Excellence (NICE) decision to not provide people living with certain rare blood cancers access to POTELIGEO® (mogamulizumab).
Download
04 March 2021

Kyowa Kirin Receives Positive CHMP Opinion for the Expanded Use of CRYSVITA® (burosumab) to Include Older Adolescents and Adults for the Treatment of X-Linked Hypophosphataemia (XLH).
Download
24 July 2020